RUNX3 antibodies are essential tools for studying the RUNX3 protein, a member of the RUNX family of transcription factors (RUNX1. RUNX2. RUNX3) that regulate gene expression in development, differentiation, and disease. RUNX3. encoded by the *RUNX3* gene, plays dual roles as a tumor suppressor and an immune regulator. It is frequently silenced or downregulated in cancers, particularly gastric, colorectal, and lung cancers, often through promoter hypermethylation, contributing to tumor progression. In immunity, RUNX3 is critical for T-cell development, dendritic cell function, and mucosal immunity.
Antibodies targeting RUNX3 enable researchers to detect its expression, localization, and interactions in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies (monoclonal or polyclonal) are validated for specificity against distinct epitopes, often distinguishing RUNX3 from other RUNX family members. Studies using RUNX3 antibodies have elucidated its role in TGF-β signaling, apoptosis, and epithelial-mesenchymal transition, highlighting its therapeutic potential. However, variability in antibody performance across experimental conditions (e.g., fixation methods) requires careful validation. Overall, RUNX3 antibodies are vital for exploring its biological functions, cancer mechanisms, and diagnostic or prognostic applications in oncology and immunology.